{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 52,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a column-based layout to map specific drug brands and pipeline assets to five major oncology therapeutic areas.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/46",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Dato-DxD = datopotamab deruxtecan; EGFR = epidermal growth factor receptor; c-MET = mesenchymal-epithelial transition factor; ADC = antibody-drug conjugate; PARP1sel = poly ADP ribose polymerase-1 selective; CD3xCD19 = cluster of differentiation 3 and cluster of differentiation 19 bispecific; TCE = T cell engager; CDK9 = cyclin-dependent kinase 9; AKTi = protein kinase B inhibitor; BCL2-xL = B-cell lymphoma-extra large; PD1 = programmed cell death protein 1; TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; GPC3 = glypican 3 protein; CAR-T = chimeric antigen receptor t-cell; CLDN18.2 = Claudin-18.2. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DxD), Merck & Co., Inc. (Lynparza); Compugen (rilvegostomig).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6baadaab-29b3-4947-8f3d-1b96834cd769",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Icons representing Lung, Breast, Haematology, GI, and GYN/GU",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f7a45f9-6e95-47b5-8d16-b5b18f6d4fb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Lists of drug assets under each tumour area column",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2903929f-0462-4669-87b3-cf19481a135b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "metric",
      "text": "38, 16, 6, 21, 29",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "972ba47f-4fd1-4956-ba5f-46c7e5d84f10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "subtitle",
      "text": "DATA PRESENTATIONS BY TUMOUR AREA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afa6b172-85a5-445c-afa1-8da398772f0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "ASCO 2023 data reinforces potential to transform patient outcomes in key tumour areas",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1783fbe-872a-42b4-abc1-86c0abfd49b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Strengthening oncology leadership",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1ca1d61-332a-4d6c-9cf9-708890a3e1f1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 52,
      "from": 26,
      "beatId": "a55635e0-23e3-4936-80d1-f995ad7f0061",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with a roadmap for future growth, potential new options for patients, and a summary of key messages",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}